Dthera Sciences (DTHR) S-1 27 Sep 18 2018 Q2 IPO registration Financial data

Document and Entity Information

Document and Entity Information - USD ($)	6 Months Ended
	Jun. 30, 2018	Aug. 10, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Dthera Sciences
Entity Central Index Key	1,586,372
Document Type	S1
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	Yes
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 96,304,827
Entity Common Stock, Shares Outstanding		51,410,508
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 70,192	$ 323,483	$ 12,191
Restricted cash	20,000
Prepaid expenses	630,014	95,176	0
Deposits	3,200	2,500	1,000
TOTAL CURRENT ASSETS	723,406	421,159	13,191
LONG TERM ASSETS
Property and equipment, net	88,957	77,365	914
Computer software development costs, net	186,420
TOTAL LONG TERM ASSETS	275,377	77,365	914
TOTAL ASSETS	998,783	498,524	14,105
CURRENT LIABILITIES
Accounts payable and accrued liabilities	529,228	429,015	272,079
Deferred revenues	3,945	1,800	0
Derivative liabilities	100,000	0	234,502
Notes payable		0	20,000
Related party advances		7,457	0
Convertible notes payable, net		0	67,345
TOTAL CURRENT LIABILITIES	633,173	438,272	593,926
TOTAL LIABILITIES	633,173	438,272	593,926
Preferred stock, 20,000,000 shares authorized. $0.001 par value; redeemable preferred stock series A, 150,000 designated; $0.0001 par value; 0 and 112,690 shares issued and outstanding as at December 31, 2017 and 2016, respectively		0	11
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock	2,532	2,352	602
Additional paid in capital	6,404,805	4,594,847	1,397,966
Accumulated deficit	(6,041,727)	(4,536,947)	(1,978,400)
Total Stockholders' Deficit	365,610	60,252	(579,821)
Total Liabilities and Stockholders' Deficit	$ 998,783	$ 498,524	$ 14,105

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value		$ 0.001	$ .0001
Preferred stock, authorized/designated		20,000,000	1,000,000
Common stock Par value	$ 0.001	$ 0.001	$ 0.001
Common stock, Authorized	600,000,000	600,000,000	600,000,000
Common stock, Issued	2,532,064	2,352,165	603,020
Common stock, outstanding	2,532,064	2,352,165	603,020
Redeemable Preferred Stock [Member]
Preferred stock, authorized/designated		150,000	150,000
Preferred stock, shares issued		112,690	112,690
Preferred stock, shares outstanding		112,690	112,690

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
REVENUES
Sales	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Cost of services					0	0
GROSS PROFIT					0	0
OPERATING EXPENSES
Depreciation					1,165	6,159
General and administrative	835,521	1,245,545	1,418,305	1,582,382	1,809,076	690,248
Research and development	53,488	75,699	78,188	91,334	0	0
Professional fees					613,705	343,694
TOTAL OPERATING EXPENSES	889,009	1,321,244	1,496,493	1,673,716	2,423,946	1,040,101
OPERATING LOSS	(889,009)	(1,321,244)	(1,496,493)	(1,673,716)	(2,423,946)	(1,040,101)
OTHER INCOME (EXPENSES)
Interest expense	(1,837)	0	(2,117)	(185,847)	(185,843)	(126,115)
Derivative expense	0	0	0	142,835	0	(37,616)
Gain on derivative liability	0	0	0	(91,593)	142,835	33,114
Gain (loss) on extinguishment of debt					(91,593)	34,874
Impairment of intangible assets					0	(58,960)
Loss on disposal of fixed assets	(3,391)	0	(6,170)	0
TOTAL OTHER INCOME (EXPENSES)	(5,228)	0	(8,287)	(134,605)	(134,601)	(154,703)
NET LOSS	$ (894,237)	$ (1,321,244)	$ (1,504,780)	$ (1,808,321)	$ (2,558,547)	$ (1,194,804)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and diluted	2,530,205	360,307	2,464,806	672,372	1,292,477	396,127
Loss per common share - Basic and diluted	$ (.35)	$ (3.67)	$ (0.61)	$ (2.69)	$ (1.98)	$ (3.02)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2015	0	239,219
Beginning balance, value at Dec. 31, 2015	$ 0	$ 239	$ 87,254	$ (783,596)	$ (696,103)
Common stock issued for cash, shares		5,242
Common stock issued for cash, value		$ 5	62,895		62,900
Common stock issued for services, shares		7,306
Common stock issued for services, value		$ 7	41,868		41,875
Common stock issued for patent, shares		10,269
Common stock issued for patent, value		$ 10	58,950		58,960
Common stock issued for conversion of debt, shares		73,150
Common stock issued for conversion of debt, value		$ 73	730,101		730,174
Common stock issued in lieu of interest, shares		1,167
Common stock issued in lieu of interest, value		$ 1	6,699		6,700
Preferred stock issued for conversion of debt, shares	112,690
Preferred stock issued for conversion of debt, value	$ 11		112,679		112,690
Fair value of options vested			241,433		241,433
Common stock issued for merger agreement, shares		266,667
Common stock issued for merger agreement, value		$ 267	56,087		56,354
Net loss				(1,194,804)	(1,194,804)
Ending balance, shares at Dec. 31, 2016	112,690	603,020
Ending balance, value at Dec. 31, 2016	$ 11	$ 602	1,397,966	(1,978,400)	(579,821)
Redemption of preferred stock for cash, shares	(112,690)
Redemption of preferred stock for cash, value	$ (11)		(112,679)		(112,690)
Common stock issued for cash, shares		1,747,757
Common stock issued for cash, value		$ 1,748	2,933,504		2,935,252
Common stock issued in extinguishment of debt, shares		1,388
Common stock issued in extinguishment of debt, value		$ 1	183,268		183,269
Fair value of options vested			192,789		192,789
Net loss				(2,558,547)	(2,558,547)
Ending balance, shares at Dec. 31, 2017	0	2,352,165
Ending balance, value at Dec. 31, 2017	$ 0	$ 2,351	$ 4,474,344	$ (4,536,947)	$ 60,252
Common stock issued for services, shares					90,000
Net loss					$ (1,504,780)
Ending balance, value at Jun. 30, 2018					$ 365,610

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (1,504,780)	$ (1,808,321)	$ (2,558,547)	$ (1,194,804)
Adjustments for non-cash items:
Depreciation	1,856	433	1,165	734
Amortization of debt discount	0	172,655	172,655	72,771
Loss on disposal of fixed assets	6,170	0
Impairment of intangible assets			0	58,960
Stock issued for services	39,177	0	0	16,750
(Gain)/Loss on extinguishment of debt			91,593	(34,874)
Gain on derivative liability	0	91,593	(142,835)	(33,114)
Initial derivative expense	0	(142,835)	0	37,616
Fair value of options vested	214,805	1,051,538	192,789	241,433
Operating expense paid in behalf of the company			46,618	20,627
Changes in operating assets and liabilities:
Prepaid expenses	(534,838)	0	(95,176)	21,390
Deposits	(700)	0	(1,500)	0
Accounts payable and accrued liabilities	94,901	(104,038)	156,945	291,891
Deferred revenue			1,800	58,773
NET CASH USED IN OPERATING ACTIVITIES	(1,683,409)	(738,975)	(2,134,493)	(441,847)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(19,618)	(49,866)	(77,616)	0
Development of software	(186,420)	0
NET CASH USED IN INVESTING ACTIVITIES	(206,038)	(49,866)	(77,616)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock	1,556,156	1,215,750	2,935,252	62,900
Proceeds from issuance of notes payable, related parties			0	94,000
Proceeds from issuance of notes payable	100,000	50,000	50,000	20,000
Payments on notes payable	0	(70,000)	(70,000)	0
Proceeds from issuance of convertible notes payable			0	330,000
Payments on notes payable, related parties			0	(80,100)
Payments on related party advances			(39,161)	0
Payments on convertible notes payable	0	(240,000)	(240,000)	0
Redemption of series A preferred stock			(112,690)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,656,156	955,750	2,523,401	426,800
NET CHANGE IN CASH AND CASH EQUIVALENTS	(233,291)	166,909	311,292	(15,047)
CASH AND CASH EQUIVALENTS - Beginning of period	323,483	12,191	12,191	27,238
CASH AND CASH EQUIVALENTS - End of period	70,192	179,100	323,483	12,191
Cash paid for interest	465	19,890	19,890	0
Cash paid for taxes	800	800
NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued for assets			0	58,960
Common stock issued for interest			0	6,700
Preferred shares issued for debt			0	112,690
Shares issued in settlement of debt			0	731,391
Assets & liabilities settled in share exchange			0	56,355
Debt discount on convertible debt			0	240,000
Common stock issued in extinguishment of debt	$ 0	$ 183,260	$ 183,260	$ 0

1. Condensed Financial Statemen

1. Condensed Financial Statements (June 2018 Note)	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Financial Statements	NOTE 1– CONDENSED FINANCIAL STATEMENTS The accompanying financial statements of Dthera Sciences (the “Company”) have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2018, and for all periods presented herein, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2017 audited financial statements. The results of operations for the periods ended June 30, 2018 and 2017, are not necessarily indicative of the operating results for the full years.

1. Summary of Significant Accou

1. Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business Dthera Sciences is a Nevada corporation. The Company, based in San Diego, CA, is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company’s lead product, ReminX™, is an artificial-intelligence-powered consumer health product designed to digitally deliver reminiscence therapy to individuals suffering from neurodegenerative diseases such as Dementia and Alzheimer’s disease, as well as seniors experiencing limited social interaction with others (“Social Isolation”). Additional products are under development that are expected to directly target the symptoms of Alzheimer’s disease and other dementias, such as anxiety, depression, and cognitive decline, and for which Company may seek FDA clearance or approval as well as reimbursement. Accounting Basis The Company’s financial statements are prepared using the accrual basis of accounting in accordance with U.S. GAAP. The Company has a December 31 fiscal year end. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates are made in relation to the fair value of certain financial instruments. Principles of Consolidation The consolidated financial statements include the accounts of Dthera Sciences and its subsidiaries. All significant inter-company accounts and transactions have been eliminated. Software Development The Company accounts for internal use software development costs in accordance with authoritative guidance related to accounting for the costs of application and web software developed or obtained for internal use. Software development costs that are incurred in the preliminary development stage are expensed as incurred. Once certain criteria have been met (“application development stage”), direct costs incurred in developing or obtaining computer software are capitalized. Costs in the post-implementation/operation stage, including costs related to training and software maintenance, are expensed as incurred. Some costs in post-implementation stage can be capitalized if the modifications add additional functionality in the future. The application development stage begin in the first fiscal quarter of 2018 and the post-implementation/operation stage is expected to be reached in the third fiscal quarter of 2018. Research and Development The Company engages in new software and hardware development efforts. Research and development expenses relating to possible future software and hardware are expensed as incurred. Research and development expenses were $53,488 and $78,188 for the three and six months ended June 30, 2018, respectively, and $75,699 and $91,334 for the three and six months ended June 30, 2017, respectively. Reclassification Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation. Professional Fees and Depreciation are presented with General and Administrative expenses. Research and Development costs have been presented separately from General and Administrative expenses. Related Party Advances are presented with Accounts Payable and Accrued Liabilities and Restricted Cash is presented separately from Cash. Loss Per Common Share Basic loss per Common Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per Common Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding stock options and warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities. For the six months ended June 30, 2018 and Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customer (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) (“ASU 2018-07”). ASU 2018-07 provides for improvements to nonemployee share-based payment accounting by expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The awards will be measured at grant date, consistent with accounting for employee share-based payment awards. The measurement date has been redefined as the date at which the grantor and grantee reach a mutual understanding of the key terms and conditions of the award. The requirement to reassess classification of equity-classified awards upon vesting has been eliminated. ASU 2018-07 will have a material impact on the Company’s financial statements as a significant number of options were granted to nonemployees. The Company will adopt ASU 2018-07 in the third fiscal quarter of 2018.	Description of Business Dthera Sciences (formerly Knowledge Machine International, Inc.) is a Nevada corporation. The Company, based in San Diego, CA, is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company’s lead product, ReminX, is an artificial-intelligence-powered consumer health product designed to digitally deliver reminiscence therapy to individuals suffering from neurodegenerative diseases such as Dementia and Alzheimer’s disease, as well as seniors experiencing limited social interaction with others (“Social Isolation”). Additional products are under development that are expected to directly target the symptoms of Alzheimer’s disease and other dementias, such as anxiety, depression, and cognitive decline, and for which Company may seek FDA clearance or approval as well as reimbursement. The Company was incorporated in the State of Nevada on December 27, 2012, to engage in the distribution of high end edged tools produced outside the United States. On October 22, 2014, we acquired an operating subsidiary, Knowledge Machine, Inc., a Nevada corporation, (“Knowledge Machine”), which focused on new technologies, acquiring licensing rights to those technologies, and marketing the licensed technologies, and the Company sold off its edged tools business. Subsequently, on September 21, 2016, the Company acquired a new operating subsidiary, EveryStory, Inc., a Delaware corporation (“EveryStory”). In connection with the EveryStory transaction, the Company dissolved the Knowledge Machine subsidiary, terminated the technology licensing and marketing operations, and changed the Company’s name to Dthera Sciences. Effective July 25, 2017, a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-3 (one share of new common stock for each three shares of old common stock) (the “Reverse Split”), took effect in the market, following a filing of a Certificate of Change with the State of Nevada and authorization from the Financial Industry Regulatory Authority (“FINRA”). Effective October 17, 2017, the Company filed its Certificate of Amendment (the “Amendment”) with the Secretary of State of Nevada to increase authorized common shares from 66,666,667 shares to 600,000,000 shares, and to increase the authorized preferred stock from 1,000,000 to 20,000,000 shares. Effective October 17, 2017, the Company filed its Certificate of Amendment (the “Amendment”) with the Secretary of State of Nevada to increase authorized common shares from 66,666,667 shares to 600,000,000 shares, and to increase the authorized preferred stock from 1,000,000 to 20,000,000 shares. Accounting Basis The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The Company has a December 31 fiscal year end. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates are made in relation to the allowance for doubtful accounts and the fair value of certain financial instruments. Principles of Consolidation The consolidated financial statements include the accounts of Dthera Sciences and its subsidiaries. All significant inter-company accounts and transactions have been eliminated. Cash and Cash Equivalents Cash and cash equivalents include all cash balances and highly liquid investments with an original maturity of three months or less. As of December 31, 2017 and 2016, the Company’s cash balances were within the FDIC insurance coverage limits. Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable & accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The Company accounts for its derivative liabilities and non-employee stock options, at fair value, on a recurring basis under level 2. Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under Accounting Standards Codification 815, Derivatives and Hedging Debt with Conversion and Other Options Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including stock purchase options and convertible debt, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For convertible debt with embedded derivatives, the Company uses the Binomial Lattice model to value the embedded derivatives. Debt Issuance Costs and Debt Discount The Company may record debt issuance costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity. These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed. Concentration of Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash. Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States. The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limits. The risk is managed by maintaining all deposits in high quality financial institutions. For the year ended December 31, 2017 and 2016, there were no customers that accounted for a material portion of total revenues. Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment: Description Useful Lives Office Equipment and Computers 2 to 3 years Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred. Valuation of Long-Lived Assets Long-lived tangible assets and definite-lived intangible assets are reviewed for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company uses both an estimate of undiscounted future net cash flows of the assets over the remaining useful lives and a replacement cost method when determining their fair values. If the carrying values of the assets exceed the fair value of the assets, the Company recognizes an impairment loss equal to the difference between the carrying values of the assets and their fair values. Impairment of long-lived assets is assessed at the lowest levels for which there are identifiable cash flows that are independent from other groups of assets. The evaluation of long-lived assets requires the Company to use estimates of future cash flows. However, actual cash flows may differ from the estimated future cash flows used in these impairment tests. Revenue Recognition The Company recognizes revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered to the customer, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Where arrangements have multiple elements, revenue is allocated to the elements based on the relative selling price method and revenue is recognized based on the Company’s policy for each respective element. Software Development The Company accounts for internal use software development costs in accordance with authoritative guidance related to accounting for the costs of app and web software developed or obtained for internal use. Software development costs that are incurred in the preliminary development stage are expensed as incurred. Once certain criteria have been met (“application development stage”), direct costs incurred in developing or obtaining computer software are capitalized. Costs in the post-implementation/operation stage, including costs related to training and software maintenance, are expensed as incurred. Research and Development The Company engages in new software development efforts. Research and development expenses relating to possible future software are expensed as incurred. Research and development expenses were approximately $0 for the years ended December 31, 2017 and 2016. Advertising Expenses The Company expenses advertising costs as incurred. Advertising may consist of media or online advertising and marketing. As such, advertising expenses were approximately $395,446 and $86,037 for the years ended December 31, 2017 and 2016, respectively. Stock-Based Compensation The Company accounts for share based payments in accordance with ASC 718, Compensation - Stock Compensation Measurement Objective – Fair Value at Grant Date Compensation cost is recognized over the requisite service period, which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized common stock. ASC 505, Compensation-Stock Compensation Loss Per Common Share Basic loss per Common Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per Common Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding convertible Preferred Stock, stock options, warrants, and convertible debt. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities. For the years ended December 31, 2017 and 2016, all of the Company’s potentially dilutive securities (options and convertible debt) were excluded from the computation of diluted earnings per share as they were anti-dilutive. The total number of potentially dilutive Common Shares that were excluded were 6,883,388 and 1,198,733 at the years ended December 31, 2017 and 2016, respectively. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date. The Company follows ASC 740 Income Taxes The Company’s policy is to recognize both interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties on unrecognized tax benefits expected to result in payment of cash within one year are classified as accrued liabilities, while those expected beyond one year are classified as other liabilities. The Company has not recorded any interest and penalties since its inception. The Company files income tax returns in the U.S. federal tax jurisdiction and various state tax jurisdictions. The tax years for 2013 to 2017 remain open for federal and/or state tax jurisdictions. The Company is currently not under examination by any other tax jurisdictions for any tax years. Recent Accounting Pronouncements Management has considered all other recent accounting pronouncements issued since the last audit of the Company’s consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

2. Going Concern

2. Going Concern	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 – GOING CONCERN The Company's financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of the date of this Report, the Company had an accumulated deficit of $ The future of the Company as an operating business will depend on its ability to (1) obtain sufficient capital contributions and/or financing as may be required to sustain its operations, and (2) to achieve adequate revenues from its operations. Management's plan to address these issues includes, (a) continued exercise of tight cost controls to conserve cash, (b) obtaining additional financing, (c) placing revenue producing products into place, and (d) identifying and executing on additional revenue generating opportunities. There is a risk that the Company will be unable to achieve the above results or obtain adequate financing on terms considered satisfactory to the Company, or at all.	The Company’s consolidated financial statements are presented on the accrual basis of accounting and accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has sustained substantial losses from operations since commencement of operations and at December 31, 2017, the Company had an accumulated deficit of $4,536,947 and a working capital deficit of $17,113, and no revenues to cover its operating costs. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. As of the date of this Report, the Company had not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The future of the Company as an operating business will depend on its ability to (1) obtain sufficient capital contributions and/or financing as may be required to sustain its operations, and (2) to achieve adequate revenues from its operations. Management's plan to address these issues includes, (a) continued exercise of tight cost controls to conserve cash, (b) obtaining additional financing, (c) placing revenue producing services into place, and (d) identifying and executing on additional revenue generating opportunities. There is a risk that the Company will be unable to achieve the above results or obtain adequate financing on terms considered satisfactory to the Company, or at all.

3. Property and Equipment

3. Property and Equipment	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 4 – PROPERTY AND EQUIPMENT The Company’s property and equipment were comprised of the following as of June 30, 2018, and December 31, 2017: June 30, 2018 December 31, 2017 Computer and Equipment $ 10,805 $ 10,237 Assets Used to Fulfill Contract Obligations 82,284 70,195 Less: Accumulated Depreciation (4,132) (3,067) Net Property and Equipment $ 88,957 $ 77,365 Depreciation on the assets used to fulfill contract obligations will begin when put into use and will be depreciated over a 3-year period. Depreciation expense for the three and six months ended June 30, 2018 was $900 and $1,856, respectively. Depreciation expense for the three and six months ended June 30, 2017, was $255 and $433, respectively. The Company recorded a loss on disposal of fixed assets in the three and six-months ended June 30, 2018 of $3,391 and $6,170, respectively, with no related expense in the three and six months ended June 30, 2017.	The Company’s property and equipment were comprised of the following as of December 31, 2017 and 2016: December 31, December 31, Computer and Equipment 10,237 2,816 Assets Used to Fulfill Contract Obligations 70,195 – Less: Accumulated Depreciation (3,067 ) (1,902 ) Net Property and Equipment $ 77,365 $ 914

5. Computer Software Developmen

5. Computer Software Development Costs (June 2018 Note)	6 Months Ended
	Jun. 30, 2018
Research and Development [Abstract]
Computer Software Development Costs	NOTE 5 – COMPUTER SOFTWARE DEVELOPMENT COSTS The Company’s capitalized application development stage costs related to computer software development under ASC 350-40 “Intangibles-Goodwill and Other- Internal-Use Software” No amortization expense has been recognized for the capitalized software development costs through June 30, 2018. Amortization on these capitalized software development costs will begin when placed in service and will be amortized over the life of the software.

4. Loans Payable

4. Loans Payable	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Loans Payable	NOTE 6 – NOTES PAYABLE On May 11, 2018, the Company issued a short-term promissory note to an unrelated party for $50,000 due 30 days from the date of issuance. The note bears an interest rate of 14.4% per annum, and the Company has the right to pre-pay with no penalty or premium. The Company’s obligation to repay the note was secured by the grant of a security interest in the assets of the Company. On June 10, 2018, the Company extended the term of the above short-term promissory note of $50,000 to October 31, 2018. All other terms remained the same. On June 28, 2018, the Company issued a short-term promissory note to an unrelated party for $50,000 due 90 days from the date of issuance. The note bears interest at a rate of 12% per annum, and the Company has the right to pre-pay with no penalty or premium. The Company’s obligation to repay the note was secured by the grant of a security interest in the assets of the Company.	Related Party Advances Notes payable due to related parties consisted of the following as of December 31, 2017 and 2016: Balance December 31, 2016 $ – Cash additions – Expense additions 46,618 Cash payments (39,161 ) Balance December 31, 2017 $ 7,457 In 2017, the Company’s CEO had expense additions of $46,618, and was repaid $39,161. Notes Payable Notes payable consisted of the following as of December 31, 2017 and 2016: Balance December 31, 2016 $ 20,000 Cash additions 50,000 Expense additions – Cash payments (70,000 ) Balance December 31, 2017 $ – On August 3, 2016, the Company entered into a promissory note purchase agreement with an unrelated individual for $20,000. This note was due on demand. On April 13, 2017, the Company repaid the balance in full. On February 3, 2017, the Company issued a short-term note to an unrelated third-party individual for $50,000 due on demand. The note bore an interest rate of 10% per annum interest within the 90-day period and would increase to 20% interest if not fully paid back within 90 days. On April 9, 2017, the Company repaid the balance in full. Convertible Notes Payable Notes payable due to non-related parties consisted of the following as of December 31, 2017, and December 31, 2016: Balance December 31, 2016, net of discount $ 67,345 Conversions – Cash payments (240,000 ) Amortization of debt discount 172,655 Balance December 31, 2017 $ – Effective September 22, 2016, the Company conducted a private offering of convertible notes (the “Note Offering”) to raise additional capital that would remain in the Company following the Closing of the EveryStory Transaction. In the convertible note offering, the Company raised an aggregate of $240,000, which was to be a component of the post-Closing capitalization of the Company. In the Note Offering, investors entered into a securities purchase agreement (the “Note SPA”) and were issued a convertible redeemable promissory note (collectively, the “Convertible Notes”). Pursuant to the terms of the Note SPA, each investor represented and warranted that it was an accredited investor and that he or she was purchasing the Convertible Notes for his or her own account, and not with a view to distribution, as well as other standard representations made in private transactions. Also pursuant to the Note SPA, the Company had the right to put an additional Convertible Note (in the same principal amount as purchased by the applicable investor) beginning on January 3, 2017, subject to certain conditions. The Convertible Notes bore interest at a rate of 10%, and were to mature on September 13, 2017, if not converted or prepaid prior to that. The Convertible Notes could convert into shares of the Company's common stock at a price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock as reported on the OTC Market platform on which the Company’s shares are quoted or any exchange upon which the Common Stock may be traded in the future ("Exchange"), on the date of the closing of the EveryStory Transaction. Up to 50% of the Convertible Notes could be repaid by the Company any time prior to 180 days after the issuance of the Convertible Notes, with a 30% premium to be paid in connection with the prepayment. As a result of this transaction a debt discount of $240,000 was recorded against the note. As of December 31, 2017, interest expense of $172,655 was recorded as part of the amortization of the debt discount, leaving a debt discount balance of $0 at December 31, 2017. In March 2017, the Company modified the interest rate on the Convertible Notes to 15% per annum and repaid the Convertible Notes in the original principal amount of $240,000. In connection with the repayment of the Convertible Notes, the Company repaid a total of $240,000 in principal and $18,000 in interest, and agreed to issue 83,300 pre-split/27,768 post-split shares of the Company’s common stock to the holders of the Convertible Notes. The shares of common stock were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 and regulations promulgated thereunder. Each of the holders of the Convertible Notes represented to the Company that it was an accredited investor, that it was acquiring the shares for its own account and for investment purposes, and not with an intent to distribute. The Company evaluated the amendment under ASC 470-50, Debt - Modification and Extinguishment

5. Derivative Liabilities

5. Derivative Liabilities	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	The Company evaluates its fair value hierarchy disclosures each quarter. The Company has convertible notes with embedded conversion features, which is accounted for as a derivative liability and measured at fair value on a recurring basis. At December 31, 2017, this derivative liability had an estimated fair value of $0. The following table presents information about the derivative liability, which was our only financial instrument measured at fair value on a recurring basis using significant inputs other than level one inputs that are either directly or indirectly observable (Level 3) as of December 31, 2017: Balance at December 31, 2016 $ 234,502 Conversion (91,667 ) Change in Fair Value of Derivative (142,835 ) Balance at December 31, 2017 $ – The fair value of this derivative liability was calculated using the multinomial lattice models that value the derivative liability within the notes based on a probability weighted discounted cash flow model. These models are based on future projections of the various potential outcomes. The features in the notes that were analyzed and incorporated into the model included the conversion feature with the reset provisions; redemption provisions; and the default provisions. Assumptions used to calculate the fair value of the derivative liability were as follows: December 31, 2017 Expected term in years 0.51 years Risk-free interest rates 0.89% Volatility 48.05% Dividend yield 0% In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing, if that financing is registered or not, and what that stock price would be for the financing at that time. The Company notes that the notes have matured, and that the Company is no longer calculating a derivative value for these notes.

6. Preferred Stock

6. Preferred Stock	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Preferred Stock	The Company has authorized 20,000,000 Preferred Stock, of which it has designated 150,000 shares of $0.0001 par value per share Series A Redeemable Preferred Stock (“Series A Preferred Stock”). The Series A Preferred Stock has a stated value of $1.00 per share, of which 0 and 112,690 shares were issued and outstanding as of December 31, 2017 and 2016, respectively. During the year ended December 31, 2017, the Company redeemed 112,690 shares of Series A Preferred Stock with a stated value of $1.00 per share for $112,690. Series A Redeemable Preferred Stock The Series A Preferred Stock have the following rights and preferences: · Redeemable at any time at the option of the holder for cash on a dollar-per-dollar basis at a redemption of $1.00 per share. · Convertible into shares of Common Stock using a conversion price of $0.10 per share. · No general voting rights until converted into Common Stock. · Entitled to receive dividends at a rate per annum of 8%. · Liquidation preference upon a liquidation event. On October 17, 2017, the Company filed a Certificate of Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada to increase authorized preferred stock from 1,000,000 to 20,000,000 shares.

7. Common Stock

7. Common Stock	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Equity [Abstract]
Common Stock	NOTE 7 – COMMON STOCK The Board of Directors of the Company approved a one for twenty reverse stock split that became effective September 25, 2018. The effect of this reverse stock split has been retroactively reflected in these financial statements. As of June 30, 2018, the Company was authorized to issue 600,000,000 shares of $0.001 par value per share Common Stock, of which 50,641,277 and 47,043,304 shares were issued outstanding as of June 30, 2018, and December 31, 2017, respectively. During the six months ended June 30, 2018, the Company issue 3,211,108 shares of Common Stock for $1,524,350 in cash in connection with a private placement offering. During the six months ended June 30, 2018, option holders exercised 296,865 options at $0.11 per share of common stock for $31,806. During the six months ended June 30, 2018, the Company issued 90,000 shares of common stock in exchange for strategic advisory services. The fair value of the stock compensation was $39,177 of which $13,059 was recognized in general and administrative expenses for the three and six months ended June 30, 2018 with the remainder in prepaid assets for future services.	The Board of Directors of the Company approved a one for twenty reverse stock split that became effective September 25, 2018. The effect of this reverse stock split has been retroactively reflected in these financial statements. As of December 31, 2017, the Company was authorized to issue 600,000,000 shares of $0.001 par value per share Common Stock, of which 47,043,268 and 12,060,367 shares were issued outstanding as of December 31, 2017 and 2016, respectively. On October 17, 2017, the Company filed the Amendment with the Secretary of State of Nevada, which also increased the authorized common shares from 66,666,667 shares to 600,000,000 shares. Year Ended December 31, 2017 The Company conducted three private offerings which closed during the year ended December 31, 2017 as summarized below. Investor Offering The first private offering was offered to investors (the “Investor Offering”), in which the Company sold units (the “Units”) which consisted of four (4) shares of the Company’s common stock and warrants to purchase one (1) additional share of common stock. The per Unit price was $0.12, and the exercise price for the warrants is $0.45. The warrants cannot be exercised until two years from the purchase date (subject to certain conditions), and expire four years after the purchase date. As of the closing of the Investor Offering, the Company had sold an aggregate of 26,215,499 post-split shares of its common stock in the Investor Offering and issued warrants to purchase an additional 6,553,860 post-split shares of its common stock. Employee/Consultant Offering The second private offering was offered to employees and consultants of the Company (the “Employee Offering”), in which the Company sold shares of its common stock at a purchase price of $0.03 per share, the same price as in the Investor Offering; however, there were no warrants in the Employee Offering. The shares sold in the Employee Offering include restrictions on their resale, and the Company reserved the right to repurchase the shares (the “Repurchase Right”) on terms as agreed between the Company and the employee or consultant. Per the Employee and Consultant Share Purchase Agreement, the Company’s Repurchase Rights will terminate (subject to certain conditions) following a term of not less than 5 months or more than 36 months from the purchase date. As of the date of the closing of the Employee Offering, the Company had sold an aggregate of 5,201,333 shares of its common stock in the Employee Offering. The aggregate amount raised by the Company in the Investor Offering and the Employee Offering as of the closing of the two offerings was $942,502. The foregoing summary of the terms and conditions of the Employee Offering does not purport to be complete, and is qualified in its entirety by reference to the full text of the Employee and Consultant Share Purchase Agreement which was filed as an exhibit to a Current Report on Form 8-K filed on July 25, 2017. The securities offered and sold and to be sold by the Company in the Investor Offering and the Employee Offering were not and will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Investor Offering and the Employee Offering were made in reliance on the private offering exemption of Section 4(a)(2) of the Securities Act and/or the private offering safe harbor provisions of Rule 506 of Regulation D based on the following factors: (i) the number of offerees or purchasers, as applicable, (ii) the absence of general solicitation, (iii) investment representations obtained from the security holders in each of the transactions, (iv) the provision of appropriate disclosure, and (v) the placement of restrictive legends on the certificates reflecting the securities. Prior Private Offering Also, during year ended December 31, 2017, pursuant to another private placement offering conducted and closed earlier in the calendar year (the “Prior Private Offering”). The Company issued 2,342,924 post-split shares of common stock for gross proceeds of $1,215,750. On March 10, 2017, the Company issued 83,300 pre-split shares/27,768 post-split shares of the Company’s common stock to the holders of the Convertible Notes as part of the modification and settlement of the notes, fair-valued at $183,260. Pre-Launch Offering The Company commenced a private placement offering of shares of its common stock (the “Pre-launch Offering”) in the fourth quarter of 2017. As of year-end the Company had sold a total of 1,195,385 shares of the Company's Common Stock for net proceeds of $777,000 in the Pre-launch Offering. Year Ended December 31, 2016 On June 5, 2016, EveryStory issued 88,000 shares of its common stock, which were exchanged for 616,133 shares of Dthera common stock for the purchase agreement for an SIT Patent for a value of $58,960. On August 3, 2016, EveryStory issued On September 15, 2016, EveryStory issued 25,000 shares of its common stock, which were exchanged for 175,038 shares of Dthera common stock valued at $16,750 for services . On September 16, 2016, EveryStory issued 37,500 shares of its common stock, which were exchanged for 263,325 shares of Dthera common stock valued at $25,125 in settlement of $60,000 of accrued consulting fees . This resulted in a gain on settlement of $34,874. On September 21, 2016, as part of the A&R Agreement, EveryStory issued 625,033 shares of its common stock, which were exchanged for 4,388,997 shares of Dthera common stock, for the conversion of debt for a value of $730,174. In connection with the A&R Agreement, the parties agreed that the prior shareholders of the Company would own an aggregate of 16,000,000 post-split shares of the Company’s common stock as part of the agreement totaling $56,354. The reverse stock split is discussed in more detail in Note 1 above. From November to December 2016 the Company issued 314,500 shares of common stock at $0.20 per share for cash proceeds of $62,900, pursuant to the private placement offering.

8. Stock Purchase Options

8. Stock Purchase Options	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Purchase Options	NOTE 8 – STOCK OPTIONS AND WARRANTS Stock Purchase Options On March 21, 2018, the Company’s Board of Directors voted to grant to sixteen individuals options to purchase up to an aggregate of 1,500,000 shares of the Company’s common stock. The terms of the options are as follows: the options vest one-third on the first anniversary of the date of grant; one-third on the second anniversary of the date of grant; and one-third on the third anniversary of the date of grant; the options have a contractual life of eight years from the date of grant; and the exercise price is $0.65, which was the market price of the options on the date of the grant. Included in the grants were options to purchase up to 250,000 shares to the Company’s President and Chief Executive Officer, and options to purchase up to 250,000 shares to the Company’s Chief Technical Officer. The options were not issued pursuant to a stock option or stock incentive plan. On April 6, 2018, the Company’s Board of Directors approved the grant of 250,000 shares of the Company’s common stock to the newest member of the Board of Directors. The terms of the options are as follows: the options vest one-third on the first anniversary of the date of grant; one-third on the second anniversary of the date of grant; and one-third on the third anniversary of the date of grant; the options have a contractual life of eight years from the date of grant; and the exercise price is $0.65. On June 13, 2018, the Company’s Board of Directors approved the grant of 60,000 options to purchase shares of the Company’s common stock, to a consultant in exchange for services. The options granted had an exercise price of $0.45 per share. One-sixth of the options shall vest each month for six months, the first one-sixth will vest in June 2018 and the last one-sixth will vest in November 2018. The grants expire on the eighth anniversary of the date of grant. On June 28, 2018, the Company’s Board of Directors approved the grant of an aggregate of 600,000 options to purchase shares of the Company’s common stock, consisting of grants of 25,000 options to 24 employees and consultants to the Company who had been instrumental in helping the Company get to the point of the initial launch. The options granted had an exercise price of $0.42 per share, and vest one-third on each of the first, second, and third anniversaries of the date of grant, and expire on the eighth anniversary of the date of grant. On June 28, 2018, the Company’s Board of Directors approved the grant of an aggregate of 250,000 options to purchase shares of the Company’s common stock, consisting of grants of 125,000 options to two Board Members of the Company. The options granted had an exercise price of $0.42 per share, and vest one-third on each of the first, second, and third anniversaries of the date of grant, and expire on the eighth anniversary of the date of grant. As the holders of the Company’s outstanding options are employees and non-employees, the values attributable to non-employee options are re-measured on a quarterly basis and amortized over the service period and until they fully vest over a 3-year vesting period. Stock options issued to employees are valued on the date of issuance and amortized over the service period until they fully vest over a 3-year vesting period. The Company believes that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value of the non-employee stock options granted was re-measured at each reporting date using the Black-Scholes valuation model. As of June 30, 2018, the Company re-measured the unvested options at a value of $2,097,912 to be recognized over the vesting period. The Company recorded $142,914 and $214,805 of stock-based compensation expense in the three and six months ended June 30, 2018, respectively. The Company recorded $862,384 and $1,051,538 of stock-based compensation expense in the three and six months ended June 30, 2017, respectively. The following table summarizes the changes in options outstanding of the Company during the six months ending June 30, 2018: Number of Options Weighted Average Exercise Price per Share Outstanding, December 31, 2017 1,382,351 $ 0.30 Granted 2,660,000 $ 0.55 Exercised (296,865 ) $ 0.11 Cancelled (25,000 ) $ 0.65 Outstanding, June 30, 2018 3,720,486 $ 0.49 Exercisable, June 30, 2018 930,403 $ 0.35 As of June 30, 2018, the Company had $ 1,490,285 Stock Purchase Warrants During the six months ended June 30, 2018, the Company did not issue any warrants. The following table summarizes the changes in warrants outstanding during the six months ended June 30, 2018 : Number of Warrants Weighted Average Exercise Price per Share Outstanding, December 31, 2017 6,553,860 $ 0.45 Outstanding, June 30, 2018 6,553,860 $ 0.45 Exercisable, June 30, 2018 – – The warrants are contractually exercisable two years after the grant date and expire four years after the grant date. There is a 30-day mandatory exercise period triggered by the Company’s stock trading on a national exchange at a price of more than $2.50 per share for 30 consecutive trading days. If warrants are not exercised within 30 days of the mandatory exercise period termination, the warrants will be forfeited.	Stock Purchase Options During the year ended December 31, 2017, the Company did not issue any stock purchase options. As the holders of the Company’s outstanding options are employees and non-employees, the values attributable to non-employee options are remeasured on a quarterly basis and amortized over the service period and until they have fully vested over a 3 year vesting period. Stock options issued to employees are valued on the date of issuance and amortized over the service period until they have fully vested over a 3 year vesting period. The Company believes that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value of the non-employee stock options granted was revalued at each reporting date using the Black-Scholes valuation model. As of December 31, 2017, the Company remeasured the options at a value of $960,518 to be recognized over the vesting period, of which $468,280 has been recognized. The following table summarizes the changes in options outstanding of the Company during the year ending December 31, 2017: Number of Weighted Average Exercise Price $ Outstanding, December 31, 2016 1,382,351 0.29 Outstanding, December 31, 2017 1,382,351 0.29 Exercisable, December 31, 2017 1,299,808 0.29 As of December 31, 2017, the Company had $492,238 in unrecognized expense related to future vesting of stock options. Stock Purchase Warrants In 2017, the Company issued warrants to purchase a total of as part of the Investor Offering discussed above. The following table summarizes the changes in Warrants outstanding of the Company during the year ended December 31, 2017: Number of Weighted Average Exercise Price $ Outstanding, December 31, 2016 – – Outstanding, December 31, 2017 6,553,860 0.45 Exercisable, December 31, 2017 – –

9. Income Taxes

9. Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	The components of the net deferred tax asset as of December 31, 2017 and 2016: December 31, December 31, Operating loss carryforwards $ 1,542,562 $ 672,656 Depreciation & amortization (2,876 ) (2,480 ) Loss on impairment (22,460 ) (22,460 ) Stock-based compensation (182,986 ) (117,416 ) Total Deferred Tax Assets 1,334,240 530,300 Valuation allowance (1,334,240 ) (530,300 ) Net Deferred Tax Asset $ – $ – Federal and state net operating loss carryforwards were $4,536,947 and $1,978,400 as of December 31, 2017 and 2016, respectively. The net operating loss carryforwards expire between 2033 and 2037. The following is a reconciliation of the amount of provision for (benefit from) income taxes that would result from applying the federal statutory rate to pretax loss with the provision for income taxes for the years ended December 31, 2017 and 2016, respectively: December 31, December 31, Tax at statutory rate (34%) $ (869,906 ) $ (406,233 ) Non-deductible expenses 65,966 118,465 Change in valuation allowance 803,940 287,768 State tax benefit, net of federal tax effect – – Provision for Income Taxes $ – $ – The Company adopted FASB ASC 740-10-05-6 on January 1, 2013. Under FASB ASC 740-10-05-6, tax benefits are recognized only for the tax positions that are more likely than not be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the company's tax return that do not meet these recognition and measurement standards. Upon the adoption of FASB ASC 740-10-05-6, the Company had no liabilities for unrecognized tax benefits and, as such, the adoption had no impact on its financial statements, and the Company has recorded no additional interest or penalties. The Adoption of FASB ASC 740-10-05-6 did not impact the Company's effective tax rates. The Company's policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits with the income tax expense. For the years ended December 31, 2017, and 2016, the Company did not recognize any interest or penalties in its Consolidated Statements of Operations, nor did it have any interest or penalties accrued in its Consolidated Balance Sheets at December 31, 2017 and 2016 relating to unrecognized benefits. The tax years 2013 through 2017 remain open to examination for federal income tax purposes and by other major taxing jurisdictions to which the Company is subject.

10. Fair Value Measurements

10. Fair Value Measurements	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	NOTE 9 - FAIR VALUE MEASUREMENTS Equities measured at fair value on a recurring basis at June 30, 2018, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 2,097,912 $ – $ 2,097,912 Equities measured at fair value on a recurring basis at December 31, 2017, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 960,518 $ – $ 960,518 Fair value is calculated using the Black-Scholes options pricing model for options.	Liabilities measured at fair value on a recurring basis at December 31, 2017, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 960,518 $ – $ 960,518 Fair value of derivatives $ – $ – $ – $ – Fair value is calculated using the Black-Scholes options pricing model for the stock options and the Binomial Lattice model for the derivatives. Liabilities measured at fair value on a recurring basis at December 31, 2016, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 1,609,699 $ – $ 1,609,699 Fair value of derivatives $ – $ – $ 234,502 $ 234,502

11. Subsequent Events

11. Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 - SUBSEQUENT EVENTS In accordance with ASC 855, Company’s management reviewed all material events through the date of this filing and determined that there were the following material subsequent events to report: Promissory Notes On July 2, 2018, the Company issued a short-term note to an unrelated party for $100,000 due 60 days from the date of issuance. The note bears an interest rate of 12% per annum, and the Company has the right to pre-pay with no penalty or premium. The Company’s obligation to repay the note was secured by the grant of a security interest in the assets of the Company. On July 2, 2018, the Company received $50,000 for a short-term promissory note to an unrelated party due 60 days from the date of issuance. The note bears interest at a rate of 12% per annum, and the Company has the right to pre-pay with no penalty or premium. The Company’s obligation to repay the note was secured by the grant of a security interest in the assets of the Company. Sale of Common Stock On July 20, 2018, the Company received cash proceeds of $500,000 in connection with a subscription agreement with an investor to sell 769,231 common shares at $0.65 per share. This closed a private placement offering of shares of its common stock (the “Offering”). The Company had commenced the Offering in late 2017.	In accordance with ASC 855, Company’s management reviewed all material events through the date of this filing and determined that there were the following material subsequent events to report: Common Stock From January 1, 2018, through March 29, 2018, the Company issued 3,200,658 shares of Common Stock for $1,017,925 in cash in connection and $500,000 in subscription receivables with a private placement offering. On January 26, 2018, an option holder exercised 98,955 options for common stock for $10,602. On March 21, 2018, the Company’s Board of Directors voted to grant to sixteen individuals options to purchase up to an aggregate of 1,500,000 shares of the Company’s common stock. The terms of the options are as follows: the options vest one-third on the first anniversary of the date of grant; one-third on the second anniversary of the date of grant; and one-third on the third anniversary of the date of grant; the options have a contractual life of eight years from the date of grant; and the exercise price is $0.65, which was the market price of the options on the date of the grant. The number of options granted ranges from 25,000 to 250,000, depending on the individual. Included in the grants were options to purchase up to 250,000 shares to Edward Cox, the Company’s President and Chief Executive Officer, and options to purchase up to 250,000 shares to David Keene, the Company’s Chief Technical Officer. The options were not issued pursuant to a stock option or stock incentive plan. As of March 28, 2018, 1,500,000 options had been issued. Hatch Agreement On January 20, 2018, the Company entered into a Standard Services Agreement (the “SSA”) with Hatch International Limited relating to the creation and manufacture of the Tablets and related hardware. The Company agreed to pay an aggregate of $602,000 for the setup, creation, and manufacture of the initial 5,000 Tablets.

1. Summary of Significant Acc20

1. Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Description of Business	Nature of Business Dthera Sciences is a Nevada corporation. The Company, based in San Diego, CA, is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company’s lead product, ReminX™, is an artificial-intelligence-powered consumer health product designed to digitally deliver reminiscence therapy to individuals suffering from neurodegenerative diseases such as Dementia and Alzheimer’s disease, as well as seniors experiencing limited social interaction with others (“Social Isolation”). Additional products are under development that are expected to directly target the symptoms of Alzheimer’s disease and other dementias, such as anxiety, depression, and cognitive decline, and for which Company may seek FDA clearance or approval as well as reimbursement.	Description of Business Dthera Sciences (formerly Knowledge Machine International, Inc.) is a Nevada corporation. The Company, based in San Diego, CA, is a digital therapeutics company focused on developing innovative quality of life therapies for the elderly and those suffering from cognitive decline. The Company’s lead product, ReminX, is an artificial-intelligence-powered consumer health product designed to digitally deliver reminiscence therapy to individuals suffering from neurodegenerative diseases such as Dementia and Alzheimer’s disease, as well as seniors experiencing limited social interaction with others (“Social Isolation”). Additional products are under development that are expected to directly target the symptoms of Alzheimer’s disease and other dementias, such as anxiety, depression, and cognitive decline, and for which Company may seek FDA clearance or approval as well as reimbursement. The Company was incorporated in the State of Nevada on December 27, 2012, to engage in the distribution of high end edged tools produced outside the United States. On October 22, 2014, we acquired an operating subsidiary, Knowledge Machine, Inc., a Nevada corporation, (“Knowledge Machine”), which focused on new technologies, acquiring licensing rights to those technologies, and marketing the licensed technologies, and the Company sold off its edged tools business. Subsequently, on September 21, 2016, the Company acquired a new operating subsidiary, EveryStory, Inc., a Delaware corporation (“EveryStory”). In connection with the EveryStory transaction, the Company dissolved the Knowledge Machine subsidiary, terminated the technology licensing and marketing operations, and changed the Company’s name to Dthera Sciences. Effective July 25, 2017, a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-3 (one share of new common stock for each three shares of old common stock) (the “Reverse Split”), took effect in the market, following a filing of a Certificate of Change with the State of Nevada and authorization from the Financial Industry Regulatory Authority (“FINRA”). Effective October 17, 2017, the Company filed its Certificate of Amendment (the “Amendment”) with the Secretary of State of Nevada to increase authorized common shares from 66,666,667 shares to 600,000,000 shares, and to increase the authorized preferred stock from 1,000,000 to 20,000,000 shares. Effective October 17, 2017, the Company filed its Certificate of Amendment (the “Amendment”) with the Secretary of State of Nevada to increase authorized common shares from 66,666,667 shares to 600,000,000 shares, and to increase the authorized preferred stock from 1,000,000 to 20,000,000 shares.
Accounting Basis	Accounting Basis The Company’s financial statements are prepared using the accrual basis of accounting in accordance with U.S. GAAP. The Company has a December 31 fiscal year end.	Accounting Basis The Company’s financial statements are prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The Company has a December 31 fiscal year end.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates are made in relation to the fair value of certain financial instruments.	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates are made in relation to the allowance for doubtful accounts and the fair value of certain financial instruments.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Dthera Sciences and its subsidiaries. All significant inter-company accounts and transactions have been eliminated.	Principles of Consolidation The consolidated financial statements include the accounts of Dthera Sciences and its subsidiaries. All significant inter-company accounts and transactions have been eliminated.
Cash and Cash Equivalents		Cash and Cash Equivalents Cash and cash equivalents include all cash balances and highly liquid investments with an original maturity of three months or less. As of December 31, 2017 and 2016, the Company’s cash balances were within the FDIC insurance coverage limits.
Fair value of Financial Instruments		Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable & accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The Company accounts for its derivative liabilities and non-employee stock options, at fair value, on a recurring basis under level 2.
Embedded Conversion Features		Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under Accounting Standards Codification 815, Derivatives and Hedging Debt with Conversion and Other Options
Derivative Financial Instruments		Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including stock purchase options and convertible debt, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For convertible debt with embedded derivatives, the Company uses the Binomial Lattice model to value the embedded derivatives.
Debt Issuance Costs and Debt Discount		Debt Issuance Costs and Debt Discount The Company may record debt issuance costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity. These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.
Concentration of Risk		Concentration of Risk Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash. Our cash balances are maintained in accounts held by major banks and financial institutions located in the United States. The Company occasionally maintains amounts on deposit with a financial institution that are in excess of the federally insured limits. The risk is managed by maintaining all deposits in high quality financial institutions. For the year ended December 31, 2017 and 2016, there were no customers that accounted for a material portion of total revenues.
Property and Equipment		Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following depreciable lives for its major classifications of property and equipment: Description Useful Lives Office Equipment and Computers 2 to 3 years Expenditures associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred.
Valuation of Long-Lived Assets		Valuation of Long-Lived Assets Long-lived tangible assets and definite-lived intangible assets are reviewed for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company uses both an estimate of undiscounted future net cash flows of the assets over the remaining useful lives and a replacement cost method when determining their fair values. If the carrying values of the assets exceed the fair value of the assets, the Company recognizes an impairment loss equal to the difference between the carrying values of the assets and their fair values. Impairment of long-lived assets is assessed at the lowest levels for which there are identifiable cash flows that are independent from other groups of assets. The evaluation of long-lived assets requires the Company to use estimates of future cash flows. However, actual cash flows may differ from the estimated future cash flows used in these impairment tests.
Revenue Recognition		Revenue Recognition The Company recognizes revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered to the customer, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Where arrangements have multiple elements, revenue is allocated to the elements based on the relative selling price method and revenue is recognized based on the Company’s policy for each respective element.
Software Development	Software Development The Company accounts for internal use software development costs in accordance with authoritative guidance related to accounting for the costs of application and web software developed or obtained for internal use. Software development costs that are incurred in the preliminary development stage are expensed as incurred. Once certain criteria have been met (“application development stage”), direct costs incurred in developing or obtaining computer software are capitalized. Costs in the post-implementation/operation stage, including costs related to training and software maintenance, are expensed as incurred. Some costs in post-implementation stage can be capitalized if the modifications add additional functionality in the future. The application development stage begin in the first fiscal quarter of 2018 and the post-implementation/operation stage is expected to be reached in the third fiscal quarter of 2018.	Software Development The Company accounts for internal use software development costs in accordance with authoritative guidance related to accounting for the costs of app and web software developed or obtained for internal use. Software development costs that are incurred in the preliminary development stage are expensed as incurred. Once certain criteria have been met (“application development stage”), direct costs incurred in developing or obtaining computer software are capitalized. Costs in the post-implementation/operation stage, including costs related to training and software maintenance, are expensed as incurred.
Research and Development	Research and Development The Company engages in new software and hardware development efforts. Research and development expenses relating to possible future software and hardware are expensed as incurred. Research and development expenses were $53,488 and $78,188 for the three and six months ended June 30, 2018, respectively, and $75,699 and $91,334 for the three and six months ended June 30, 2017, respectively.	Research and Development The Company engages in new software development efforts. Research and development expenses relating to possible future software are expensed as incurred. Research and development expenses were approximately $0 for the years ended December 31, 2017 and 2016.
Advertising Expenses		Advertising Expenses The Company expenses advertising costs as incurred. Advertising may consist of media or online advertising and marketing. As such, advertising expenses were approximately $395,446 and $86,037 for the years ended December 31, 2017 and 2016, respectively.
Stock-Based Compensation		Stock-Based Compensation The Company accounts for share based payments in accordance with ASC 718, Compensation - Stock Compensation Measurement Objective – Fair Value at Grant Date Compensation cost is recognized over the requisite service period, which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized common stock. ASC 505, Compensation-Stock Compensation
Loss Per Common Share	Loss Per Common Share Basic loss per Common Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per Common Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding stock options and warrants. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities. For the six months ended June 30, 2018 and	Loss Per Common Share Basic loss per Common Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per Common Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding convertible Preferred Stock, stock options, warrants, and convertible debt. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities. For the years ended December 31, 2017 and 2016, all of the Company’s potentially dilutive securities (options and convertible debt) were excluded from the computation of diluted earnings per share as they were anti-dilutive. The total number of potentially dilutive Common Shares that were excluded were 6,883,388 and 1,198,733 at the years ended December 31, 2017 and 2016, respectively.
Income Taxes		Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The charge for taxation is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date. The Company follows ASC 740 Income Taxes The Company’s policy is to recognize both interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties on unrecognized tax benefits expected to result in payment of cash within one year are classified as accrued liabilities, while those expected beyond one year are classified as other liabilities. The Company has not recorded any interest and penalties since its inception. The Company files income tax returns in the U.S. federal tax jurisdiction and various state tax jurisdictions. The tax years for 2013 to 2017 remain open for federal and/or state tax jurisdictions. The Company is currently not under examination by any other tax jurisdictions for any tax years.
Reclassification	Reclassification Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation. Professional Fees and Depreciation are presented with General and Administrative expenses. Research and Development costs have been presented separately from General and Administrative expenses. Related Party Advances are presented with Accounts Payable and Accrued Liabilities and Restricted Cash is presented separately from Cash.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customer (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) (“ASU 2018-07”). ASU 2018-07 provides for improvements to nonemployee share-based payment accounting by expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The awards will be measured at grant date, consistent with accounting for employee share-based payment awards. The measurement date has been redefined as the date at which the grantor and grantee reach a mutual understanding of the key terms and conditions of the award. The requirement to reassess classification of equity-classified awards upon vesting has been eliminated. ASU 2018-07 will have a material impact on the Company’s financial statements as a significant number of options were granted to nonemployees. The Company will adopt ASU 2018-07 in the third fiscal quarter of 2018.	Recent Accounting Pronouncements Management has considered all other recent accounting pronouncements issued since the last audit of the Company’s consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

3. Property and Equipment (Tabl

3. Property and Equipment (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and equipment schedule	June 30, 2018 December 31, 2017 Computer and Equipment $ 10,805 $ 10,237 Assets Used to Fulfill Contract Obligations 82,284 70,195 Less: Accumulated Depreciation (4,132) (3,067) Net Property and Equipment $ 88,957 $ 77,365	December 31, December 31, Computer and Equipment 10,237 2,816 Assets Used to Fulfill Contract Obligations 70,195 – Less: Accumulated Depreciation (3,067 ) (1,902 ) Net Property and Equipment $ 77,365 $ 914

4. Loans Payable (Tables)

4. Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of related party advances	Balance December 31, 2016 $ – Cash additions – Expense additions 46,618 Cash payments (39,161 ) Balance December 31, 2017 $ 7,457
Schedule of notes payable	Balance December 31, 2016 $ 20,000 Cash additions 50,000 Expense additions – Cash payments (70,000 ) Balance December 31, 2017 $ –
Schedule of convertible notes payable	Balance December 31, 2016, net of discount $ 67,345 Conversions – Cash payments (240,000 ) Amortization of debt discount 172,655 Balance December 31, 2017 $ –

5. Derivative Liabilities (Tabl

5. Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liability - Level 3	Balance at December 31, 2016 $ 234,502 Conversion (91,667 ) Change in Fair Value of Derivative (142,835 ) Balance at December 31, 2017 $ –
Assumptions	December 31, 2017 Expected term in years 0.51 years Risk-free interest rates 0.89% Volatility 48.05% Dividend yield 0%

8. Stock Purchase Options (Tabl

8. Stock Purchase Options (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Option activity	Number of Options Weighted Average Exercise Price per Share Outstanding, December 31, 2017 1,382,351 $ 0.30 Granted 2,660,000 $ 0.55 Exercised (296,865 ) $ 0.11 Cancelled (25,000 ) $ 0.65 Outstanding, June 30, 2018 3,720,486 $ 0.49 Exercisable, June 30, 2018 930,403 $ 0.35	Number of Weighted Average Exercise Price $ Outstanding, December 31, 2016 1,382,351 0.29 Outstanding, December 31, 2017 1,382,351 0.29 Exercisable, December 31, 2017 1,299,808 0.29
Schedule of warrants outstanding	Number of Warrants Weighted Average Exercise Price per Share Outstanding, December 31, 2017 6,553,860 $ 0.45 Outstanding, June 30, 2018 6,553,860 $ 0.45 Exercisable, June 30, 2018 – –	Number of Weighted Average Exercise Price $ Outstanding, December 31, 2016 – – Outstanding, December 31, 2017 6,553,860 0.45 Exercisable, December 31, 2017 – –

9. Income Taxes (Tables)

9. Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of net deferred tax assets	December 31, December 31, Operating loss carryforwards $ 1,542,562 $ 672,656 Depreciation & amortization (2,876 ) (2,480 ) Loss on impairment (22,460 ) (22,460 ) Stock-based compensation (182,986 ) (117,416 ) Total Deferred Tax Assets 1,334,240 530,300 Valuation allowance (1,334,240 ) (530,300 ) Net Deferred Tax Asset $ – $ –
Reconciliation of income taxes	December 31, December 31, Tax at statutory rate (34%) $ (869,906 ) $ (406,233 ) Non-deductible expenses 65,966 118,465 Change in valuation allowance 803,940 287,768 State tax benefit, net of federal tax effect – – Provision for Income Taxes $ – $ –

10. Fair Value Measurements (Ta

10. Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Liabilities measured at fair value on a recurring basis at December 31, 2017, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 960,518 $ – $ 960,518 Fair value of derivatives $ – $ – $ – $ – Liabilities measured at fair value on a recurring basis at December 31, 2016, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 1,609,699 $ – $ 1,609,699 Fair value of derivatives $ – $ – $ 234,502 $ 234,502

1. Summary of Significant Acc27

1. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Reverse stock split					Effective July 25, 2017, at a ratio of 1-for-3
Property and equipment useful lives					2 to 3 years
Research and development	$ 53,488	$ 75,699	$ 78,188	$ 91,334	$ 0	$ 0
Advertising expense					$ 395,446	$ 86,037
Antidilutive shares excluded from EPS					6,883,388	1,198,733

2. Going Concern (Details Narra

2. Going Concern (Details Narrative) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (6,041,727)	$ (4,536,947)	$ (1,978,400)
Working capital		$ (17,113)

3. Property and Equipment (Deta

3. Property and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Computer and equipment	$ 10,805	$ 10,237	$ 2,816
Assets used to fulfill contract obligations	82,284	70,195	0
Less: Accumulated depreciation	(4,132)	(3,067)	(1,902)
Net property and equipment	$ 88,957	$ 77,365	$ 914

4. Loans Payable (Details - Rel

4. Loans Payable (Details - Related Parties) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance, beginning	$ 0
Cash payments	(39,161)	$ 0
Balance, ending	7,457	0
Notes Payable Related Party [Member]
Balance, beginning	0
Cash additions	0
Expense additions	46,618
Cash payments	(39,161)
Balance, ending	$ 7,457	$ 0

4. Loans Payable (Details - Not

4. Loans Payable (Details - Notes Payable) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Balance, beginning	$ 0	$ 20,000	$ 20,000
Cash payments	0	(70,000)	(70,000)	$ 0
Balance, ending			0	20,000
Notes Payable [Member]
Balance, beginning	$ 0	$ 20,000	20,000
Cash additions			50,000
Expense additions			0
Cash payments			(70,000)
Balance, ending			$ 0	$ 20,000

4. Loans Payable (Details - Con

4. Loans Payable (Details - Convertible Notes) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Balance, beginning	$ 0	$ 67,345	$ 67,345
Cash payments	0	(240,000)	(240,000)	$ 0
Amortization of debt discount	0	172,655	172,655	72,771
Balance, ending			0	67,345
Convertible Notes Payable [Member]
Balance, beginning	$ 0	$ 67,345	67,345
Conversions			0
Cash payments			(240,000)
Amortization of debt discount			172,655
Balance, ending			$ 0	$ 67,345

4. Loans Payable (Details Narra

4. Loans Payable (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Operating expense paid in behalf of the company			$ 46,618	$ 20,627
Proceeds from convertible debt			0	330,000
Repayment of convertible note	$ 0	$ 240,000	240,000	0
Loss on extinguishment of debt			(91,593)	34,874
Convertible Note [Member]
Proceeds from convertible debt				240,000
Debt discount			0	$ 240,000
Interest expense			172,655
Repayment of convertible note			240,000
Repayment of interest			$ 18,000
Debt converted, shares issued			27,768
Loss on extinguishment of debt			$ (91,593)
Chief Executive Officer [Member]
Operating expense paid in behalf of the company			46,618
Repayment of operating expenses			$ 39,161
Interest rate			0.00%

5. Derivative Liabilities (Deta

5. Derivative Liabilities (Details - Level 3) - Convertible Notes [Member]	12 Months Ended
	Dec. 31, 2017USD ($)
Derivative liability, beginning balance	$ 234,502
Conversion	(91,667)
Change in Fair Value of Derivative	(142,835)
Derivative liability, ending balance	$ 0

5. Derivative Liabilities (De35

5. Derivative Liabilities (Details - Assumptions)	12 Months Ended
	Dec. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Expected term in years	0.51 years
Risk-free interest rates	0.89%
Volatility	48.05%
Dividend yield	0.00%

6. Preferred Stock (Details Nar

6. Preferred Stock (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.001	$ .0001
Preferred stock, authorized/designated	20,000,000	1,000,000
Payments for repurchase of redeemable preferred stock	$ 112,690	$ 0
Series A Preferred Stock [Member] | August 7, 2017 [Member]
Payments for repurchase of redeemable preferred stock	$ 42,690
Shares of stock redeemed	42,690
Series A Preferred Stock [Member] | August 18, 2017 [Member]
Payments for repurchase of redeemable preferred stock	$ 20,000
Shares of stock redeemed	20,000
Series A Preferred Stock [Member] | September 11, 2017 [Member]
Payments for repurchase of redeemable preferred stock	$ 20,000
Shares of stock redeemed	20,000
Series A Preferred Stock [Member] | October 10, 2017 [Member]
Payments for repurchase of redeemable preferred stock	$ 25,000
Shares of stock redeemed	25,000
Series A Preferred Stock [Member] | November 16, 2017 [Member]
Payments for repurchase of redeemable preferred stock	$ 5,000
Shares of stock redeemed	5,000
Redeemable Preferred Stock [Member]
Preferred stock, authorized/designated	150,000	150,000
Preferred stock, shares issued	112,690	112,690
Preferred stock, shares outstanding	112,690	112,690

7. Common Stock (Details Narrat

7. Common Stock (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Common stock Par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, Authorized	600,000,000	600,000,000	600,000,000	600,000,000
Common stock, Issued	2,352,165	2,532,064	2,352,165	603,020
Common stock, outstanding	2,352,165	2,532,064	2,352,165	603,020
Stock issued for patent, value				$ 58,960
Stock issued for services, shares		90,000
Stock issued for services, value				41,875
Gain on settlement of debt			$ (91,593)	$ 34,874
Private Placement [Member]
Stock issued new, shares	2,342,924	3,211,108		314,500
Proceeds from private placement	$ 1,215,750	$ 1,524,350		$ 62,900
Pre-Launch Offering [Member]
Stock issued new, shares	1,195,385
Proceeds from private placement	$ 777,000
EveryStory [Member] | Common Stock | Pre-Split [Member]
Stock issued for patent, shares				88,000
Stock issued for patent, value				$ 58,960
Conversion of interest, stock issued				10,000
Conversion of interest, amount converted				$ 6,700
Stock issued for services, shares				25,000
Stock issued for services, value				$ 16,750
Stock issued for settlement of accrued consulting fees, shares				37,500
Stock issued for settlement of accrued consulting fees, value				$ 25,125
Gain on settlement of debt				$ 34,874
Conversion of debt, stock issued				625,033
Conversion of debt, amount converted				$ 730,174
Dthera [Member] | Common Stock | Post-Split [Member]
Stock issued for patent, shares				616,133
Stock issued for services, shares				175,038
Stock issued for settlement of accrued consulting fees, shares				263,325
Conversion of debt, stock issued				4,388,997
Shares owned post-split				16,000,000
Value of shares owned				$ 56,354
Convertible Notes Modification [Member]
Stock issued for modification and settlement of notes, shares issued			27,768
Stock issued for modification and settlement of notes, value			$ 183,260
Investor Offering [Member]
Stock issued new, shares			26,215,499
Warrants issued			6,553,848
Employee Offering [Member]
Stock issued new, shares			5,201,333
Investor and Employee Offering [Member]
Proceeds from private placement			$ 942,502
Prior Private Offering [Member]
Stock issued new, shares			2,342,924
Proceeds from private placement			$ 1,215,750

8. Stock Purchase Options (Deta

8. Stock Purchase Options (Details - Option activity) - Equity Option [Member] - $ / shares	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Options
Options outstanding	3,720,486	1,382,351	1,382,351
Options exercisable	930,403	1,299,808
Weighted Average Exercise Price
Weighted average exercise price, options outstanding	$ 0.49	$ 0.29	$ 0.29
Weighted average exercise price, options exercisable	$ 0.35	$ 0.29

8. Stock Purchase Options (De39

8. Stock Purchase Options (Details - Warrants Ouststanding) - Stock Purchase Warrants [Member] - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Number of Warrants
Warrants outstanding	6,553,860	0
Warrants exercisable	0	0
Weighted Average Exercise Price
Weighted average exercise price	$ .45	$ 0
Weighted average exercise price - exercisable	$ 0	$ 0

8. Stock Purchase Options (De40

8. Stock Purchase Options (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options granted, value	$ 960,517
Share based compensation	$ 330,486

9. Income Taxes (Details - Defe

9. Income Taxes (Details - Deferred Tax) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Operating loss carryforwards	$ 1,542,562	$ 672,656
Depreciation & amortization	(2,876)	(2,480)
Loss on impairment	(22,460)	(22,460)
Stock-based compensation	(182,986)	(117,416)
Total Deferred Tax Assets	1,334,240	530,300
Valuation allowance	(1,334,240)	(530,300)
Net Deferred Tax Asset	$ 0	$ 0

9. Income Taxes (Details - Tax

9. Income Taxes (Details - Tax Reconciliation) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Tax at statutory rate (34%)	$ (869,906)	$ (406,233)
Non-deductible expenses	65,966	118,465
Change in valuation allowance	803,940	287,768
State tax benefit, net of federal tax effect	0	0
Provision for Income Taxes	$ 0	$ 0

9. Income Taxes (Details Narrat

9. Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 4,536,947	$ 1,978,400
Loss carryforward beginning expiration date	Dec. 31, 2033

10. Fair Value Measurements (De

10. Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Fair value of options	$ 2,097,912	$ 960,518	$ 1,609,699
Fair value of derivatives		0	234,502
Fair Value, Inputs, Level 1 [Member]
Fair value of options	0	0	0
Fair value of derivatives		0	0
Fair Value, Inputs, Level 2 [Member]
Fair value of options	2,097,912	960,518	1,609,699
Fair value of derivatives		0	0
Fair Value, Inputs, Level 3 [Member]
Fair value of options	$ 0	0	0
Fair value of derivatives		$ 0	$ 234,502

4. Property and Equipment (June

4. Property and Equipment (June 2018 Note) (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 900	$ 255	$ 1,856	$ 433	$ 1,165	$ 734
Loss on disposal of fixed assets	$ (3,391)	$ 0	$ (6,170)	$ 0

5. Computer Software Developm46

5. Computer Software Development Costs (June 2018 Note) (Details Narrative)	6 Months Ended
	Jun. 30, 2018USD ($)
Research and Development [Abstract]
Capitalized software development costs	$ 186,420
Amortization of software development costs	$ 0

6. Notes Payable (June 2018 Not

6. Notes Payable (June 2018 Note) (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Sep. 30, 2017
Note Payable 1 [Member]
Debt issuance date	May 11, 2018
Debt face value	$ 50,000
Debt stated interest rate	14.40%
Note Payable 2[Member]
Debt issuance date	Jun. 28, 2018
Debt face value		$ 50,000
Debt stated interest rate		12.00%

7. Common Stock (June 2018 Note

7. Common Stock (June 2018 Note) (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2018	Dec. 31, 2016
Common stock Par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, Authorized	600,000,000	600,000,000	600,000,000	600,000,000
Common stock, Issued	2,532,064	2,352,165	2,532,064	603,020
Common stock, outstanding	2,532,064	2,352,165	2,532,064	603,020
Stock issued in exchange of strategic advisory services, shares			90,000
Fair value of stock compensation	$ 39,177		$ 13,059
Options Exercised [Member]
Stock issued upon exercise of options, shares			296,865
Options exercised, exercise price			$ 0.11
Proceeds from options exercised			$ 31,806
Private Placement [Member]
Stock issued new, shares		2,342,924	3,211,108	314,500
Proceeds from private placement		$ 1,215,750	$ 1,524,350	$ 62,900

8. Stock Purchase Options and W

8. Stock Purchase Options and Warrants (June 2018 Note) (Details - Option activity) - Equity Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Number of Options
Options outstanding, beginning balance	1,382,351
Options granted	2,660,000
Options exercised	(296,865)
Options cancelled	(25,000)
Options outstanding, ending balance	3,720,486
Options exercisable	930,403	1,299,808
Weighted Average Exercise Price
Weighted average exercise price, options outstanding beginning	$ 0.29
Weighted average exercise price, options granted	0.55
Weighted average exercise price, options exercised	0.11
Weighted average exercise price, options cancelled	0.65
Weighted average exercise price, options outstanding ending	0.49
Weighted average exercise price, options exercisable	$ 0.35	$ 0.29

8. Stock Purchase Options and50

8. Stock Purchase Options and Warrants (June 2018 Note) (Details - Warrants) - Warrants [Member] - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Warrants outstanding	6,553,860	6,553,860
Warrants exercisable	0
Weighted average exercise price	$ 0.45	$ 0.45
Weighted average exercise price, exercisable	$ 0

9. Fair Value Measurements (Jun

9. Fair Value Measurements (June 2018 Note) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Fair value of options	$ 2,097,912	$ 960,518	$ 1,609,699
Fair Value, Inputs, Level 1 [Member]
Fair value of options	0	0	0
Fair Value, Inputs, Level 2 [Member]
Fair value of options	2,097,912	960,518	1,609,699
Fair Value, Inputs, Level 3 [Member]
Fair value of options	$ 0	$ 0	$ 0